Clinical pharmacology of GP53,633--a new non-steroidal anti-inflammatory drug--in patients with rheumatoid arthritis.
GP53,633 is a new basic non-steroidal anti-inflammatory drug showing analgesic and anti-inflammatory activity in animal models. Pharmacokinetic studies in 6 patients with rheumatoid arthritis show it to be rapidly absorbed with a short half life (approximately 2 hours). No change in pharmacokinetics is seen over a two week treatment period. Clinical parameters of inflammation were reduced and no adverse reactions were seen.